Published in J Clin Invest on June 01, 2008
Insulin reveals Akt signaling as a novel regulator of norepinephrine transporter trafficking and norepinephrine homeostasis. J Neurosci (2010) 1.25
Neuroplasticity signaling pathways linked to the pathophysiology of schizophrenia. Neurosci Biobehav Rev (2010) 1.24
DRD2/AKT1 interaction on D2 c-AMP independent signaling, attentional processing, and response to olanzapine treatment in schizophrenia. Proc Natl Acad Sci U S A (2010) 1.11
Evaluating the links between schizophrenia and sleep and circadian rhythm disruption. J Neural Transm (Vienna) (2012) 1.05
DISC1 in schizophrenia: genetic mouse models and human genomic imaging. Schizophr Bull (2010) 1.04
Genetic associations of brain structural networks in schizophrenia: a preliminary study. Biol Psychiatry (2010) 0.97
Peptide sharing between influenza A H1N1 hemagglutinin and human axon guidance proteins. Schizophr Bull (2013) 0.93
Group II metabotropic glutamate receptor agonist ameliorates MK801-induced dysfunction of NMDA receptors via the Akt/GSK-3β pathway in adult rat prefrontal cortex. Neuropsychopharmacology (2011) 0.92
AKT1 moderation of cannabis-induced cognitive alterations in psychotic disorder. Neuropsychopharmacology (2011) 0.92
Clozapine interaction with phosphatidyl inositol 3-kinase (PI3K)/insulin-signaling pathway in Caenorhabditis elegans. Neuropsychopharmacology (2009) 0.90
Molecular substrates of altered axonal growth and brain connectivity in a mouse model of schizophrenia. Neuron (2015) 0.89
GSK-3β activity and hyperdopamine-dependent behaviors. Neurosci Biobehav Rev (2010) 0.88
Marked reduction of AKT1 expression and deregulation of AKT1-associated pathways in peripheral blood mononuclear cells of schizophrenia patients. PLoS One (2012) 0.84
AKT1 genotype moderates the acute psychotomimetic effects of naturalistically smoked cannabis in young cannabis smokers. Transl Psychiatry (2016) 0.77
New repeat polymorphism in the AKT1 gene predicts striatal dopamine D2/D3 receptor availability and stimulant-induced dopamine release in the healthy human brain. J Neurosci (2017) 0.76
Genome-wide association study of working memory brain activation. Int J Psychophysiol (2016) 0.75
Thioridazine has potent antitumor effects on lung cancer stem-like cells. Oncol Lett (2017) 0.75
An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell (2005) 5.60
Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet (2004) 4.71
Prefrontal cortex and basal ganglia control access to working memory. Nat Neurosci (2007) 4.21
Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci U S A (2004) 3.60
Control of dendritic arborization by the phosphoinositide-3'-kinase-Akt-mammalian target of rapamycin pathway. J Neurosci (2005) 3.13
A beta-arrestin 2 signaling complex mediates lithium action on behavior. Cell (2008) 2.76
Recent advances in the protein kinase B signaling pathway. Curr Opin Cell Biol (2005) 2.71
Genes, dopamine and cortical signal-to-noise ratio in schizophrenia. Trends Neurosci (2004) 2.50
The Akt-GSK-3 signaling cascade in the actions of dopamine. Trends Pharmacol Sci (2007) 2.22
Regulation of Akt signaling by D2 and D3 dopamine receptors in vivo. J Neurosci (2007) 1.93
Transcriptional and behavioral interaction between 22q11.2 orthologs modulates schizophrenia-related phenotypes in mice. Nat Neurosci (2005) 1.91
State-dependent Ras signaling and AMPA receptor trafficking. Genes Dev (2005) 1.86
Control of synaptic strength, a novel function of Akt. Neuron (2003) 1.73
Mapping of deletion and translocation breakpoints in 1q44 implicates the serine/threonine kinase AKT3 in postnatal microcephaly and agenesis of the corpus callosum. Am J Hum Genet (2007) 1.54
Akt1 deficiency affects neuronal morphology and predisposes to abnormalities in prefrontal cortex functioning. Proc Natl Acad Sci U S A (2006) 1.44
Genetic variation in AKT1 is linked to dopamine-associated prefrontal cortical structure and function in humans. J Clin Invest (2008) 1.43
AKT1 is associated with schizophrenia across multiple symptom dimensions in the Irish study of high density schizophrenia families. Biol Psychiatry (2007) 1.30
Insulin receptor deficits in schizophrenia and in cellular and animal models of insulin receptor dysfunction. Schizophr Res (2006) 1.25
Cognition, drug treatment, and functional outcome in schizophrenia: a tale of two transitions. Am J Psychiatry (2007) 0.99
Strong association of de novo copy number mutations with sporadic schizophrenia. Nat Genet (2008) 10.19
Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet (2004) 4.71
Exome sequencing supports a de novo mutational paradigm for schizophrenia. Nat Genet (2011) 4.67
Altered brain microRNA biogenesis contributes to phenotypic deficits in a 22q11-deletion mouse model. Nat Genet (2008) 3.76
Spontaneous neural activity is required for the establishment and maintenance of the olfactory sensory map. Neuron (2004) 3.50
De novo gene mutations highlight patterns of genetic and neural complexity in schizophrenia. Nat Genet (2012) 3.49
Impaired hippocampal-prefrontal synchrony in a genetic mouse model of schizophrenia. Nature (2010) 2.92
Evidence that the gene encoding ZDHHC8 contributes to the risk of schizophrenia. Nat Genet (2004) 2.77
Modeling madness in mice: one piece at a time. Neuron (2006) 2.60
22q11.2 microdeletions: linking DNA structural variation to brain dysfunction and schizophrenia. Nat Rev Neurosci (2010) 2.54
A mutation in mouse Disc1 that models a schizophrenia risk allele leads to specific alterations in neuronal architecture and cognition. Proc Natl Acad Sci U S A (2008) 2.37
Disc1 is mutated in the 129S6/SvEv strain and modulates working memory in mice. Proc Natl Acad Sci U S A (2006) 2.32
Palmitoylation-dependent neurodevelopmental deficits in a mouse model of 22q11 microdeletion. Nat Neurosci (2008) 1.92
Genetic variation at the 22q11 PRODH2/DGCR6 locus presents an unusual pattern and increases susceptibility to schizophrenia. Proc Natl Acad Sci U S A (2002) 1.92
Transcriptional and behavioral interaction between 22q11.2 orthologs modulates schizophrenia-related phenotypes in mice. Nat Neurosci (2005) 1.91
Site-specific role of catechol-O-methyltransferase in dopamine overflow within prefrontal cortex and dorsal striatum. J Neurosci (2007) 1.75
The molecular genetics of the 22q11-associated schizophrenia. Brain Res Mol Brain Res (2004) 1.74
Elucidating the genetic architecture of familial schizophrenia using rare copy number variant and linkage scans. Proc Natl Acad Sci U S A (2009) 1.73
Deficiency of Dgcr8, a gene disrupted by the 22q11.2 microdeletion, results in altered short-term plasticity in the prefrontal cortex. Proc Natl Acad Sci U S A (2011) 1.65
Genetic variation in the 22q11 locus and susceptibility to schizophrenia. Proc Natl Acad Sci U S A (2002) 1.60
Evidence for association of schizophrenia with genetic variation in the 8p21.3 gene, PPP3CC, encoding the calcineurin gamma subunit. Proc Natl Acad Sci U S A (2003) 1.54
Brain catecholamine metabolism in catechol-O-methyltransferase (COMT)-deficient mice. Eur J Neurosci (2002) 1.51
Akt1 deficiency affects neuronal morphology and predisposes to abnormalities in prefrontal cortex functioning. Proc Natl Acad Sci U S A (2006) 1.44
Genetic modulation of BDNF signaling affects the outcome of axonal competition in vivo. Curr Biol (2007) 1.40
S-nitrosylation and S-palmitoylation reciprocally regulate synaptic targeting of PSD-95. Neuron (2011) 1.35
Diverse types of genetic variation converge on functional gene networks involved in schizophrenia. Nat Neurosci (2012) 1.34
Genomewide scan in families with schizophrenia from the founder population of Afrikaners reveals evidence for linkage and uniparental disomy on chromosome 1. Am J Hum Genet (2004) 1.34
Sequence variants of the brain-derived neurotrophic factor (BDNF) gene are strongly associated with obsessive-compulsive disorder. Am J Hum Genet (2003) 1.32
MicroRNAs in psychiatric and neurodevelopmental disorders. Brain Res (2010) 1.22
Effect of dopamine uptake inhibition on brain catecholamine levels and locomotion in catechol-O-methyltransferase-disrupted mice. J Pharmacol Exp Ther (2002) 1.19
Derepression of a neuronal inhibitor due to miRNA dysregulation in a schizophrenia-related microdeletion. Cell (2013) 1.19
The best of times, the worst of times for psychiatric disease. Nat Neurosci (2012) 1.18
Quantitative role of COMT in dopamine clearance in the prefrontal cortex of freely moving mice. J Neurochem (2010) 1.17
The 22q11.2 microdeletion: fifteen years of insights into the genetic and neural complexity of psychiatric disorders. Int J Dev Neurosci (2010) 1.16
The genetic architecture of schizophrenia: new mutations and emerging paradigms. Annu Rev Med (2011) 1.14
Scan statistic-based analysis of exome sequencing data identifies FAN1 at 15q13.3 as a susceptibility gene for schizophrenia and autism. Proc Natl Acad Sci U S A (2013) 1.13
Cognition in mouse models of schizophrenia susceptibility genes. Schizophr Bull (2009) 1.11
Genetic and cognitive windows into circuit mechanisms of psychiatric disease. Trends Neurosci (2011) 1.10
Altered axonal targeting and short-term plasticity in the hippocampus of Disc1 mutant mice. Proc Natl Acad Sci U S A (2011) 1.09
MicroRNA dysregulation in neuropsychiatric disorders and cognitive dysfunction. Neurobiol Dis (2012) 1.02
Resistance to salt-induced hypertension in catechol-O-methyltransferase-gene-disrupted mice. J Hypertens (2003) 1.01
Phenotypic characterization and genealogical tracing in an Afrikaner schizophrenia database. Am J Med Genet B Neuropsychiatr Genet (2004) 1.00
The pattern of cortical dysfunction in a mouse model of a schizophrenia-related microdeletion. J Neurosci (2013) 0.97
Nogo Receptor 1 (RTN4R) as a candidate gene for schizophrenia: analysis using human and mouse genetic approaches. PLoS One (2007) 0.96
Decreased phosphorylation of NMDA receptor type 1 at serine 897 in brains of patients with Schizophrenia. J Neurosci (2004) 0.95
Chronic adolescent exposure to Δ-9-tetrahydrocannabinol in COMT mutant mice: impact on psychosis-related and other phenotypes. Neuropsychopharmacology (2010) 0.93
Development of animal models for schizophrenia. Dis Model Mech (2010) 0.93
D-amphetamine responses in catechol-O-methyltransferase (COMT) disrupted mice. Psychopharmacology (Berl) (2003) 0.92
Extended intermarker linkage disequilibrium in the Afrikaners. Genome Res (2002) 0.91
The Drosophila zinc finger transcription factor CF2 is a myogenic marker downstream of MEF2 during muscle development. Mech Dev (2002) 0.91
Molecules, signaling, and schizophrenia. Curr Top Behav Neurosci (2010) 0.91
Evidence for altered hippocampal function in a mouse model of the human 22q11.2 microdeletion. Mol Cell Neurosci (2011) 0.86
Schizophrenia genetics: uncovering positional candidate genes. Eur J Hum Genet (2006) 0.86
Methoxyestradiols mediate the antimitogenic effects of 17beta-estradiol: direct evidence from catechol-O-methyltransferase-knockout mice. Circulation (2003) 0.86
Chronic adolescent exposure to delta-9-tetrahydrocannabinol in COMT mutant mice: impact on indices of dopaminergic, endocannabinoid and GABAergic pathways. Neuropsychopharmacology (2012) 0.84
Exploratory and habituation phenotype of heterozygous and homozygous COMT knockout mice. Behav Brain Res (2007) 0.84
Analysis of prepulse inhibition in mouse lines overexpressing 22q11.2 orthologues. Int J Neuropsychopharmacol (2009) 0.83
Genetic vs. pharmacological inactivation of COMT influences cannabinoid-induced expression of schizophrenia-related phenotypes. Int J Neuropsychopharmacol (2011) 0.83
Increase in free choice oral ethanol self-administration in catechol-o-methyltransferase gene-disrupted male mice. Basic Clin Pharmacol Toxicol (2008) 0.80
Physiological and behavioural responsivity to stress and anxiogenic stimuli in COMT-deficient mice. Behav Brain Res (2011) 0.80
Sexual dimorphisms in the immune system of catechol-O-methyltransferase knockout mice. Immunobiology (2012) 0.79
Genes for schizophrenia. Lancet (2003) 0.78
Lack of increased oxidative stress in catechol-O-methyltransferase (COMT)-deficient mice. Naunyn Schmiedebergs Arch Pharmacol (2004) 0.78
Sex-dependent compensated oxidative stress in the mouse liver upon deletion of catechol O-methyltransferase. Biochem Pharmacol (2009) 0.78
Stress-induced analgesia and morphine responses are changed in catechol-O-methyltransferase-deficient male mice. Basic Clin Pharmacol Toxicol (2008) 0.77
Catechol-O-methyltransferase is dispensable for vascular protection by estradiol in mouse models of atherosclerosis and neointima formation. Endocrinology (2011) 0.77
Copy number variation and psychiatric disease risk. Methods Mol Biol (2012) 0.76
Reduced natriuretic response to acute sodium loading in COMT gene deleted mice. BMC Physiol (2002) 0.75
A transient inhibition and permanent lack of catechol-O-methyltransferase have minor effects on feeding pattern of female rodents. Basic Clin Pharmacol Toxicol (2011) 0.75